| Identification | Back Directory | [Name]
SBE13 | [CAS]
775294-82-1 | [Synonyms]
SBE13
[4-(6-Chloro-pyridin-3-ylmethoxy)-3-methoxy-benzyl]-[2-(3,4-dimethoxy-phenyl)-ethyl]-amine | [Molecular Formula]
C24H27ClN2O4 | [MOL File]
775294-82-1.mol | [Molecular Weight]
442.94 |
| Chemical Properties | Back Directory | [Boiling point ]
582.8±45.0 °C(Predicted) | [density ]
1.196±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
solid | [pka]
8.67±0.19(Predicted) | [color ]
beige |
| Hazard Information | Back Directory | [Uses]
SBE13 is a potent and selective Plk1 inhibitor, with an IC50 of 200 pM; SBE13 poorly inhibits Plk2 (IC50>66?μM) or Plk3 (IC50=875?nM). | [IC 50]
PLK1: 200 pM (IC50); PLK3: 875 nM (IC50) | [storage]
Store at -20°C | [References]
[1] Keppner S, et al. Identification and validation of a potent type II inhibitor of inactive polo-like kinase 1. ChemMedChem. 2009 Nov;4(11):1806-9. DOI:10.1002/cmdc.200900338
[2] Keppner S, et al. Fate of primary cells at the G?/S boundary after polo-like kinase 1 inhibition by SBE13. Cell Cycle. 2011 Feb 15;10(4):708-20. Epub 2011 Feb 15. DOI:10.4161/cc.10.4.14898
[3] Keppner S, et al. Biological impact of freezing Plk1 in its inactive conformation in cancer cells. Cell Cycle. 2010 Feb 15;9(4):761-73. Epub 2010 Feb 16. DOI:10.4161/cc.9.4.10644 |
|
|